ZEN Graphene Solutions Ltd. Announces Upsize of Private Placement

Rhea-AI Summary

ZEN Graphene Solutions Ltd. has announced an increase in its non-brokered private placement to up to 1,400,000 units at CDN$2.50 per unit, aiming for gross proceeds of up to CDN$3,000,000. Each unit consists of one common share and one-half warrant, exercisable at CDN$3.00 for 24 months. The offering is available to existing shareholders under the Existing Security Holder Exemption. Funds will support capital expenditures, operating expenses for biocidal coating production, and further investment in intellectual property. Closing is subject to TSX Venture Exchange approval.

Positive

• Increase in private placement to 1,400,000 units, potentially raising up to CDN$3,000,000.
• Support for scaling production of biocidal coating and investment in graphene-related projects.

Negative

• None.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

THUNDER BAY, ON / ACCESSWIRE / March 26, 2021 / ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV:ZEN) is pleased to announce, in connection with its previously announced non-brokered private placement (the "Offering"), that due to higher demand the Company intends to increase the size of the Offering to up to 1,400,000 units (the "Units") at a price of CDN$2.50 per Unit for gross proceeds of up to CDN$3,000,000.

Each Unit will consist of one common share in the capital of the Company (a "Share") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each whole Warrant will be exercisable to acquire one Share at an exercise price of CDN$3.00 per Share for a period of 24 months from the date of issuance, subject to the following acceleration right. If, at any time after the date that is 4 months and one day after the date of issuance of the Warrant, the closing price of the Company's common shares on the TSX Venture Exchange (or such other stock exchange on which the common shares may be traded from time to time) is at or above CDN$4.00 per share for a period of 10 consecutive trading days (the "Triggering Event"), then the Company may accelerate the expiry date of the Warrants by giving notice thereof to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 30 calendar days after the date on which such notice is given by the Company announcing the Triggering Event.

ZEN management is happy to make the Offering available to investors in reliance on exemptions from the prospectus requirement set out in National Instrument 45-106 - Prospectus Exemptions and to existing shareholders of the Company and to investors who have received investment advice and to existing shareholders of the Company and to investors who have received investment advice in reliance on BC Instrument 45-534 Exemption from prospectus requirement for certain trades to existing security holders and the corresponding blanket orders and rules in the other Canadian jurisdictions (collectively, the "Existing Security Holder Exemption") .

The Existing Security Holder Exemption is available in each of the provinces and territories of Canada to a person or company who became a shareholder of the Company on or before March 24, 2021 and continues to be a shareholder of the Company, subject to a maximum investment of CDN$15,000 using the Existing Security Holder Exemption in a 12-month period unless the shareholder has obtained advice regarding the suitability of the investment from a person registered as an investment dealer in the shareholder's jurisdiction. As required by the Existing Security Holder Exemption, the Company confirms there is no material fact or material change relating to the Company that has not been generally disclosed.

The Offering is subject to a minimum subscription amount of CDN$2,500. All subscribers can access and complete all documents online using THIS LINK.

If the Offering is oversubscribed, unless the Company determines to increase the maximum gross proceeds of the Offering and receives approval from the TSX Venture Exchange for such increase, the Company will allocate the Units issued under the Offering to those subscribers whose subscriptions were first received by the Company. A subscription will be deemed to be received when a completed subscription agreement together with payment of the subscription amount has been received by the Company.

Certain insiders of the Company may acquire Units in the Offering. Any participation by insiders in the Private Placement would constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). However, the Company expects such participation would be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, would exceed 25% of the Company's market capitalization.

ZEN intends to use the net proceeds of the Offering: to fund capital expenditures and operating expenses at Guelph locations supporting the scale-up and production of its biocidal coating to serve existing client orders and create capacity for subsequent clients. ZEN also intends to continue to invest in ZEN's intellectual property related to graphene. Funds will also be used for general corporate purposes.

The Company may pay finder's fees on a portion of the Offering, subject to compliance with the policies of the TSX Venture Exchange and applicable securities legislation.

Closing of the Offering is subject to approval of the TSX Venture Exchange.

The securities issued under the Offering, and any Shares that may be issuable on exercise of any such securities, will be subject to a statutory hold period expiring four months and one day from the date of issuance of such securities.

About ZEN

ZEN is a next-gen nanomaterials technology company developing graphene-based technologies that help protect people and the environment. ZEN is currently focused on commercializing a patent pending graphene-based coating with 99% biocidal activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors, along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN's Albany Pure Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

CONTACT:

Brian Bosse
Director and Chief Financial Officer
ZEN Graphene Solutions Ltd.
brian@zengraphene.com
1 844 730 9822

SOURCE: ZEN Graphene Solutions Ltd.

View source version on accesswire.com:
https://www.accesswire.com/637625/ZEN-Graphene-Solutions-Ltd-Announces-Upsize-of-Private-Placement

FAQ

What is the recent announcement by ZEN Graphene Solutions Ltd. regarding their private placement?

ZEN Graphene Solutions announced an increase in its private placement to up to 1,400,000 units priced at CDN$2.50 per unit, aiming for gross proceeds of up to CDN$3,000,000.

How long are the warrants from the recent private placement valid?

The warrants are exercisable for 24 months at an exercise price of CDN$3.00 per share.

What will ZEN Graphene Solutions use the proceeds from the private placement for?

The proceeds will fund capital expenditures and operating expenses for their biocidal coating production as well as investments in intellectual property.

What is the minimum subscription amount for the private placement by ZEN Graphene Solutions?

The minimum subscription amount for the offering is CDN$2,500.

Is ZEN Graphene Solutions' private placement subject to regulatory approval?

Yes, the closing of the offering is subject to approval from the TSX Venture Exchange.